Literature DB >> 8083675

Inert placebo versus active medication. Patient blindability in clinical pharmacological trials.

A Bystritsky1, S V Waikar.   

Abstract

Patient blindability was examined in clinical, psychopharmacological, double-blind, placebo-controlled trials involving medications for obsessive-compulsive disorder and major depression. Based on the presence of clinical improvement and side effects, patients were able to determine correctly whether they took medication versus placebo. On the basis of these preliminary findings, the authors question the blindability of patients in clinical trials. Implications for the continued use of double-blind, placebo-controlled trials are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083675     DOI: 10.1097/00005053-199409000-00001

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  3 in total

1.  Improving study design for antidepressant effectiveness assessment.

Authors:  Florian Naudet; Bruno Millet; Jean Michel Reymann; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2013-08-30       Impact factor: 4.035

2.  Blindness and bias in a trial of antidepressant medication for chronic tension-type headache.

Authors:  K A Holroyd; G Tkachuk; F O'Donnell; G E Cordingley
Journal:  Cephalalgia       Date:  2006-08       Impact factor: 6.292

3.  Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care?

Authors:  Joseph C Blader
Journal:  Contemp Clin Trials       Date:  2005-03-03       Impact factor: 2.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.